MS-N145 · Cancer control · Unsupported claim · Procedure risk · Human evidence · Appraised 26 October 2026

Does medical ozone—by autohemotherapy, injection, insufflation or another route—shrink tumors or improve cancer survival?

Evidence at a glance

• Evidence label: No high-quality evidence of direct antitumor or survival benefit
• Benefit: Small heterogeneous studies do not establish tumor control; symptom or wound findings must not be converted into cancer-cure claims.
• Certainty: Low for benefit because routes, doses, comparators and endpoints vary and controlled cancer evidence is sparse.
• Risk: Route-dependent and potentially severe, including pulmonary injury with inhalation and gas embolism, stroke or death with invasive administration.

What was studied

Interventions: “Ozone therapy” covers very different procedures: mixing blood with oxygen–ozone and reinfusing it, rectal or local insufflation, ozonated oils, and direct or paravertebral injection. Safety cannot be generalized across routes.

Evidence base: Recent 2026 reviews of ozone across medical indications found heterogeneous, often small trials. Oncology reports include supportive-care and wound outcomes, but there is no high-quality evidence that ozone directly controls tumors or improves survival.

What the evidence found

A 2026 oncology-focused narrative review concluded that no high-quality evidence demonstrates a direct antitumor effect or survival improvement. Older oncology literature consists mainly of small, uncontrolled or methodologically weak studies.

Serious complications are documented. Published cases include fatal gas embolism during oxygen–ozone autohemotransfusion and cerebral gas embolism with multifocal ischemic stroke after injection procedures.

Current 21 CFR 801.415 describes ozone as a toxic gas with no known useful medical application in specific, adjunctive or preventive therapy and notes that inhaled concentrations needed for germicidal effects exceed safe tolerance.

How to interpret it

A possible effect on pain, wound healing, oxygenation or a laboratory marker would be a separate supportive-care question. It does not show that cancer growth, recurrence or survival changed.

Reviews covering back pain, dental conditions or diabetic foot care cannot be used as evidence for cancer treatment.

Practical safety context

Do not inhale ozone or accept direct gas injection into a vein. Ask exactly what route, device, sterility standard and emergency plan are proposed. Sudden chest pain, breathlessness, confusion, weakness, vision change, seizure or loss of consciousness during or after a procedure requires emergency care.

Questions for the care team

• What exact route and dose is proposed, and is the device authorized for that use?
• Does the evidence measure tumor response or survival rather than symptoms or oxygenation?
• What complications have been reported for this route, and who manages an embolic emergency?

Funding and conflicts

Recent reviews differ in scope and methodology; a complete independent assessment of every included trial’s funding was not possible. The federal regulation is a safety standard, not a clinical trial.

Sources

• 21 CFR 801.415: Maximum acceptable level of ozone
• 2026 umbrella review of ozone therapy (PMID 42346828)
• 2026 review of medical ozone and clinical evidence
• Fatal gas-embolism case (PMID 10871129)
• Cerebral gas embolism and stroke case (PMID 39720509)

Last literature search: 26 October 2026. Record appraisal: 26 October 2026. This page is educational and does not replace individualized medical advice. Laboratory effects, biomarkers, symptom changes or an uncontrolled response must not be interpreted as proof of tumor control, delayed recurrence or longer survival.